Mikko Lemola
NeOnc Technologies (NTHI) has upsized its proposed IPO to $75M from $50M.
The brain cancer therapy developer indicated in an SEC filing that it was now looking to raise $75M, but didn’t specify terms.
NeOnc hopes to list its shares on Nasdaq under the symbol NTHI. Sole bookrunner is Loop Capital Markets, with Maxim Group and Brookline Capital Markets serving as co-managers.
Based in Los Angeles, NeOnc’s lead product candidate, NEO100, is in Phase 2 testing for the treatment of recurrent malignant glioma with IDH1 mutation and meningioma. The product is also being evaluated as a drug delivery vehicle.